Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

被引:15
|
作者
Lou, Yinjun [1 ,2 ]
Ma, Yafang [1 ]
Li, Chenyin [1 ]
Suo, Sansan [1 ]
Tong, Hongyan [1 ]
Qian, Wenbin [1 ]
Mai, Wenyuan [1 ]
Meng, Haitao [1 ]
Yu, Wenjuan [1 ]
Mao, Liping [1 ]
Wei, Juyin [1 ]
Xu, Weilei [1 ]
Jin, Jie [1 ,2 ]
机构
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Inst Hematol,Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China
[2] Key Lab Hematopoiet Malignancies, Hangzhou 310003, Zhejiang, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
Philadelphia chromosome; acute lymphoblastic leukemia; imatinib; CALLG2008; STEM-CELL TRANSPLANTATION; HYPER-CVAD; CHEMOTHERAPY; DASATINIB; PONATINIB; PHASE-2;
D O I
10.1007/s11684-017-0506-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A CALLG2008 protocol was developed by the Chinese Acute Lymphoblastic Leukemia Cooperative Group for adult acute lymphoblastic leukemia (ALL). We retrospectively analyzed 153 newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL enrolled into imatinib (400 mg/d) plus CALLG2008 regimen between 2009 and 2015. The median age was 40 years (range, 18-68 years), with 81 (52.3%) males. The overall hematologic complete remission (CR) rate was 96.7% after induction. With a median follow-up of 24.2 months, the estimated 3-year overall survival (OS) and event-free survival (EFS) rates were 49.5%(95% confidence interval (CI): 38.5%-59.5%) and 49.2% (95% CI: 38.3%-59.2%), respectively. Fifty-eight (36 with haploidentical donor) patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first CR. Among the patients in CR1 after induction, both the 3-year OS and EFS were significantly better in the allo-HSCT group than in the without allo-HSCT group (73.2%, 95% CI: 58.3%-83.5% vs. 22.2%, 95% CI: 8.7%-39.6% and 66.5%, 95% CI: 50.7%-78.2% vs. 16.1%, 95% CI: 5.1%-32.7%, respectively). Multivariate analysis showed that allo-HSCT and achievement of major molecular response were associated with favorable OS or EFS independently. Interestingly, in the allo-HSCT cohort, the donor type (haploidentical versus matched donors) had no significant impact on EFS or OS. All these results suggested that imatinib plus CALLG2008 was an effective protocol for Ph-positive ALL. Haploidentical donors can also be a reasonable alternative expedient donor pool.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 50 条
  • [1] Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
    Yinjun Lou
    Yafang Ma
    Chenyin Li
    Sansan Suo
    Hongyan Tong
    Wenbin Qian
    Wenyuan Mai
    Haitao Meng
    Wenjuan Yu
    Liping Mao
    Juyin Wei
    Weilei Xu
    Jie Jin
    Frontiers of Medicine, 2017, 11 : 229 - 238
  • [2] Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience
    Tekgunduz, Emre
    Goker, Hakan
    Kaynar, Leylagul
    Sari, Ismail
    Pala, Cigdem
    Dogu, Mehmet Hilmi
    Ozturk, Erman
    Turgut, Burhan
    Korkmaz, Serdal
    Tetik, Aysegul
    Buyukasik, Yahya
    Hacioglu, Sibel Kabukcu
    Bozdag, Sinem Civriz
    Ozdemir, Evren
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (05) : 269 - 274
  • [3] Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ryuzo Ohno
    Current Oncology Reports, 2008, 10
  • [4] Blinatumomab plus ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
    Couturier, Marie-Anne
    Thomas, Xavier
    Raffoux, Emmanuel
    Huguet, Francoise
    Berthon, Celine
    Simand, Celestine
    Gallego-Hernanz, Maria-Pilar
    Hicheri, Yosr
    Berger, Mathilde Hunault
    Saillard, Colombe
    Leguay, Thibaut
    Loiseau, Clemence
    Bene, Marie-Christine
    Chevallier, Patrice
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 620 - 629
  • [5] Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Faderl, S
    Kantarjian, HM
    Thomas, DA
    Cortes, J
    Giles, F
    Pierce, S
    Albitar, M
    Estrov, Z
    LEUKEMIA & LYMPHOMA, 2000, 36 (3-4) : 263 - 273
  • [6] Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Thomas, Xavier
    Dombret, Herve
    LEUKEMIA & LYMPHOMA, 2008, 49 (07) : 1246 - 1254
  • [7] Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Stock, Wendy
    LEUKEMIA & LYMPHOMA, 2010, 51 (02) : 188 - 198
  • [8] Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
    Lim, Sung-Nam
    Joo, Young-Don
    Lee, Kyoo-Hyung
    Kim, Dae-Young
    Lee, Je-Hwan
    Lee, Jung-Hee
    Chi, Hyun-Sook
    Yun, Sung-Cheol
    Lee, Won Sik
    Lee, Sang Min
    Park, Seonyang
    Kim, Inho
    Sohn, Sang Kyun
    Moon, Joon Ho
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    Hyun, Myung Soo
    Kim, Min Kyoung
    Kim, Hyeoung Joon
    Yang, Deok-Hwan
    Eom, Hyeon-Seok
    Lee, Gyeong-Won
    Jung, Chul Won
    Won, Jong-Ho
    Kim, Hawk
    Lee, Jae-Hoon
    Shin, Ho-Jin
    Jang, Dae-Young
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (11) : 1013 - 1020
  • [9] Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Cytogenetic Study of 33 Patients Diagnosed Between 1981 and 2008
    De Braekeleer, Etienne
    Douet-Guilbert, Nathalie
    Morel, Frederic
    Le Bris, Marie-Josee
    Basinko, Audrey
    Berthou, Christian
    Morice, Patrick
    Ferec, Claude
    De Braekeleer, Marc
    ANTICANCER RESEARCH, 2010, 30 (02) : 569 - 573
  • [10] What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
    Haddad, Fadi G.
    Short, Nicholas J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 213 - 217